08:57 AM EDT, 10/03/2024 (MT Newswires) -- Halozyme Therapeutics ( HALO ) said Thursday it has expanded its global collaboration and licensing deal with argenx (ARGX) under which the latter has nominated four new targets for Halozyme's Enhanze drug delivery technology.

With the expanded agreement terms, argenx now has a total of six targets, Halozyme said.

The biopharmaceutical firm said it will receive upfront payments of $7.5 million per target nomination for a total of $30 million and future milestone payments of up to $85 million per nominated target.

Halozyme was 2.3% higher in premarket trading.

Price: 59.50, Change: +1.34, Percent Change: +2.30